The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …

The identification of EGFR mutations and their respectively tyrosine kinase inhibitors (TKIs),
changed dramatically treatment and survival of patients with EGFR-positive lung cancer …